Information about medications has traditionally been tied to print formats, which significantly limits its use and updating. At the same time, digital solutions today open up new possibilities for providing content that is more up-to-date and more easily accessible. In this context, electronic Product Information (ePI) represents a transformation that is driving lasting progress in how medication information is managed.
In this article, you’ll learn what ePI means, what benefits it offers, and why it will play an important role in the future of medicines information.
Beyond the Paper Leaflet: A New Era for Medicine Information
For generations, the primary source of information for our medicines has been the Patient Information Leaflet, a familiar piece of paper carefully folded inside every medicine carton. This document has been a cornerstone of patient safety, providing essential guidance on usage, dosage, and potential side effects.
However, in our increasingly connected and fast-paced world, the limitations of this static, paper-based system are becoming more apparent. The small print can be a barrier for those with visual impairments, the document is easily lost or discarded and updating it across millions of packages in circulation to reflect new safety information is a slow, inefficient and complex logistical challenge.
Electronic Product Information (ePI) offers a necessary evolution. By shifting authorised medicines information into the digital realm, we can make guidance more accessible, more current and more useful for patients, caregivers and healthcare professionals alike.
From Document to Data: What Makes ePI Different
To truly understand the significance of ePI, it is crucial to recognize that it represents a fundamental shift from a document-centric model to a data-centric one. ePI is not merely a PDF scan of the paper leaflet uploaded to a website. Instead, it is built upon a foundation of structured data. This means that every piece of information is tagged and organized as a discrete, machine-readable data element. This structural evolution transforms the information from a flat, passive document into an active, intelligent resource.
This architecture is what allows ePI to be dynamic, searchable, and fully interoperable, capable of seamlessly integrating with other digital health systems like Electronic Health Records, pharmacy software, and patient health apps.
Driving Forces: The Push Toward Digital Medicine Information
The transition to ePI is not a speculative concept; it is a global movement gaining significant momentum, propelled by a convergence of needs across the entire healthcare landscape. Today’s patients are more digitally literate than ever and have come to expect instant and accessible information on their personal devices. Healthcare systems and professionals are simultaneously striving for greater efficiency and a reduction in medication errors, recognizing the potential for digital tools to provide immediate, reliable data at the point of care. Most importantly, this shift is being championed by regulatory bodies worldwide.
In Europe, the EU Pharmaceutical Package prominently positions ePI as a cornerstone of regulatory modernization, aiming to harmonize standards and accelerate adoption across member states. This is signalling a clear and decisive policy direction that is accelerating adoption across the industry. The combination of user demand, clinical necessity and regulatory momentum is making the digital transition inevitable.
The Vision: Enhancing Safety and Accessibility
The implementation of ePI promises to unlock a cascade of benefits that will redefine how we interact with medicine information. For patients, this means instant access to the most current product information as well as safety warnings, with transformative features like adjustable text size, audio read-outs for the visually impaired, and on-demand multilingual translations. It empowers individuals to take a more active role in their own care.
For healthcare professionals, it means the ability to rapidly search for specific information, such as drug-drug interactions or precise dosage for specific populations, and even integrate this data directly into prescribing systems to create powerful clinical decision support tools. This vision extends to a more sustainable and efficient pharmaceutical industry, reducing the immense waste and logistical complexity associated with the printing and management of paper leaflets.
For more information, visit the Rote Liste website or contact us.